Ez Debride
OperatingEz Debride, Inc.
Healthcare · San Antonio, TX
In wound care today, a major problem encountered is a form of malicious bacteria known as biofilm, which has not historically been addressed and has led to numerous complications, including pain, infection, chronicity, and, in severe cases, loss of limb or even life. EZ Debride was invented by a surgeon, which allows focus specifically on biofilm and addresses accurate wound bed preparation–which is the first step foundationally in wound care debridement. With precise controlled depth sharp debridement, clinicians and surgeons now have the ability to overcome barriers in wound care. We believe EZ Debride, Inc represents a significant step forward in addressing longstanding challenges in wound care.
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
6 people
Dr. Francis Derk, Doctor of Podiatric Medicine and Surgery. DABPM, FACPM CAPT United States Navy: Medical Officer. Inventor and Co-Founder: MDM Wound Ventures and EZDebride. Chief Medical Officer at MDM Wound Ventures (Retired) Chief of Podiatric Medicine at South Texas Veterans Health Care System; (Retired) Assistant Clinical Professor at the University of Texas Health Science Center, (Active) Adjunct Clinical Professor at the Department of Orthopedics and Podiatric Surgery in University Texas Health Science Center; Dr. Derk has extensive military command experience, including 25+ years with foot and ankle surgery, expeditionary medicine, orthopedics, and sports medicine.
With 25+ years of diverse industry experience, including executive positions at Novartis and Merck, he excels in operational excellence, change management, and business development. He is also a sought after leader, in Ernst & Young, whose expertise benefited top FORTUNE100 companies.
A Texas based real estate industrialist with heavy background in commercial and residential real estate with an extensive portfolio. He operates and invests in Medical Devices, IoT, Technology, Farming, Restaurants, CPG, Oil and Gas businesses more specifically in SWD Facilities to help provides Total Water Management Solutions to Oil and Gas Operators.
With 25+ years as a trial attorney and Chief Legal Officer of MDM Wound Ventures, he ensures legal strategies and operational efficiency. His expertise spans contract negotiation, regulatory compliance, and risk management.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 2 annual reports (FY2024–FY2025)
Missing: 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.